Evaxion (EVAX) raises $7.2M; runway extended to H2 2027

Accepted by SEC EDGAR 10/30/2025 - 08:15 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Evaxion A/S furnished a Form 6-K announcing it issued a press release titled “Evaxion raises $7.2 million, extending cash runway to second half of 2027.” The company describes itself as a clinical-stage TechBio business developing AI-Immunology powered vaccines.

The release is included as Exhibit 99.1, and the report is incorporated by reference into Evaxion’s existing registration statements. No additional terms or financing details are provided in this excerpt.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Evaxion (EVAX) announce in this Form 6-K?

Evaxion furnished a press release titled “Evaxion raises $7.2 million, extending cash runway to second half of 2027,” attached as Exhibit 99.1.

How much capital did EVAX say it raised?

The press release title states $7.2 million.

What cash runway timeline did EVAX reference?

The press release title states the cash runway extends to the second half of 2027.

Which exhibits accompany the EVAX 6-K?

Exhibit 99.1: “Evaxion raises $7.2 million, extending cash runway to second half of 2027.”

Are the contents incorporated by reference into other EVAX filings?

Yes. The report is incorporated by reference into Evaxion’s registration statements on Forms S-8, F-3, and F-1 as listed.

What type of filer is Evaxion A/S?

Evaxion is a foreign private issuer that files annual reports on Form 20-F.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of October 2025

Commission File Number: 001-39950

Evaxion A/S
(Exact Name of Registrant as Specified in Its Charter)

Dr. Neergaards Vej 5f
DK-2970 Hoersholm
Denmark
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ]      Form 40-F [   ]

INCORPORATION BY REFERENCE

This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S’s registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

Press Release

On October 30, 2025, Evaxion A/S (the “Company”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Evaxion raises $7.2 million, extending cash runway to second half of 2027". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

Exhibits 

Exhibit No.		Description
99.1		Evaxion raises $7.2 million, extending cash runway to second half of 2027

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

			Evaxion A/S
			(Registrant)
Date: October 30, 2025		By:	/s/ Birgitte Rønø
			Birgitte Rønø
			Interim Chief Executive Officer